-DOCSTART- -X- O
Secondary -X- _ O
infection -X- _ O
with -X- _ O
a -X- _ O
heterologous -X- _ B-Patient
dengue -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
DENV -X- _ I-Patient
) -X- _ I-Patient
serotype -X- _ I-Patient
increases -X- _ O
the -X- _ O
risk -X- _ O
of -X- _ O
severe -X- _ O
dengue -X- _ O
, -X- _ O
through -X- _ O
a -X- _ O
process -X- _ O
termed -X- _ O
antibody-dependent -X- _ B-Intervention
enhancement -X- _ I-Intervention
( -X- _ I-Intervention
ADE -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
During -X- _ O
ADE -X- _ O
, -X- _ O
DENV -X- _ O
is -X- _ O
opsonized -X- _ O
with -X- _ O
non- -X- _ O
or -X- _ O
sub-neutralizing -X- _ O
antibody -X- _ O
levels -X- _ O
that -X- _ O
augment -X- _ O
entry -X- _ O
into -X- _ O
monocytes -X- _ O
and -X- _ O
dendritic -X- _ O
cells -X- _ O
through -X- _ O
Fc-gamma -X- _ O
receptors -X- _ O
( -X- _ O
FcγRs -X- _ O
) -X- _ O
. -X- _ O
We -X- _ O
previously -X- _ O
reported -X- _ O
that -X- _ O
co-ligation -X- _ B-Intervention
of -X- _ I-Intervention
leukocyte -X- _ I-Intervention
immunoglobulin-like -X- _ I-Intervention
receptor-B1 -X- _ I-Intervention
( -X- _ I-Intervention
LILRB1 -X- _ I-Intervention
) -X- _ I-Intervention
by -X- _ O
antibody-opsonized -X- _ O
DENV -X- _ O
led -X- _ O
to -X- _ O
recruitment -X- _ O
of -X- _ O
SH2 -X- _ O
domain-containing -X- _ O
phosphatase-1 -X- _ O
( -X- _ O
SHP-1 -X- _ O
) -X- _ O
to -X- _ O
dephosphorylate -X- _ B-Intervention
spleen -X- _ I-Intervention
tyrosine -X- _ I-Intervention
kinase -X- _ I-Intervention
( -X- _ I-Intervention
Syk -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ O
reduce -X- _ B-Intervention
interferon -X- _ I-Intervention
stimulated -X- _ I-Intervention
gene -X- _ I-Intervention
induction. -X- _ I-Intervention
Here -X- _ O
, -X- _ O
we -X- _ O
show -X- _ O
that -X- _ O
LILRB1 -X- _ O
also -X- _ O
signals -X- _ O
through -X- _ O
SHP-1 -X- _ O
to -X- _ O
attenuate -X- _ O
the -X- _ O
otherwise -X- _ O
rapid -X- _ O
acidification -X- _ O
for -X- _ O
lysosomal -X- _ O
enzyme -X- _ O
activation -X- _ O
following -X- _ O
FcγR-mediated -X- _ O
uptake -X- _ O
of -X- _ O
DENV. -X- _ O
Reduced -X- _ O
or -X- _ O
slower -X- _ O
trafficking -X- _ O
of -X- _ O
antibody-opsonized -X- _ O
DENV -X- _ O
to -X- _ O
lytic -X- _ O
phagolysosomal -X- _ O
compartments -X- _ O
, -X- _ O
demonstrates -X- _ O
how -X- _ O
co-ligation -X- _ O
of -X- _ O
LILRB1 -X- _ O
also -X- _ O
permits -X- _ O
DENV -X- _ O
to -X- _ O
overcome -X- _ O
a -X- _ O
cell-autonomous -X- _ O
immune -X- _ O
response -X- _ O
, -X- _ O
enhancing -X- _ O
intracellular -X- _ O
survival -X- _ O
of -X- _ O
DENV. -X- _ O
Our -X- _ O
findings -X- _ O
provide -X- _ O
insights -X- _ O
on -X- _ O
how -X- _ O
antiviral -X- _ B-Outcome
drugs -X- _ I-Outcome
that -X- _ I-Outcome
modify -X- _ I-Outcome
phagosome -X- _ I-Outcome
acidification -X- _ I-Outcome
should -X- _ O
be -X- _ O
used -X- _ O
for -X- _ O
viruses -X- _ B-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
DENV -X- _ I-Outcome
. -X- _ O

